Bionano Genomics, Inc.

NasdaqCM BNGO

Bionano Genomics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 22.95 M

Bionano Genomics, Inc. Cash and Short-Term Investments is USD 22.95 M for the quarter ending September 30, 2024, a -63.90% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Bionano Genomics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 63.58 M, a -64.71% change year over year.
  • Bionano Genomics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 180.19 M, a -44.74% change year over year.
  • Bionano Genomics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 326.07 M, a 1,628.25% change year over year.
  • Bionano Genomics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 18.87 M, a 129.39% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
Loading...
SV Wall Street
NasdaqCM: BNGO

Bionano Genomics, Inc.

CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.
IPO Date Aug. 21, 2018
Location United States
Headquarters 9540 Towne Centre Drive
Employees 344
Sector Healthcare
Industries
Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Similar companies

NVST

Envista Holdings Corp

USD 21.79

5.93%

STXS

Stereotaxis, Inc.

USD 2.44

-4.69%

MBOT

Microbot Medical Inc.

USD 2.17

6.37%

WST

West Pharmaceutical Services, Inc.

USD 330.47

-1.39%

RMD

ResMed Inc.

USD 237.18

-2.23%

BDX

Becton, Dickinson and Company

USD 227.21

-7.28%

STAA

STAAR Surgical Company

USD 22.83

-3.39%

LUCY

Innovative Eyewear, Inc.

USD 4.74

-9.02%

POAI

Predictive Oncology Inc.

USD 1.53

1.32%

NXGL

NEXGEL, Inc.

USD 3.39

-3.42%

ISRG

Intuitive Surgical, Inc.

USD 588.50

-0.41%

StockViz Staff

February 7, 2025

Any question? Send us an email